Evidence map›Paper›PMID 38962320›Full record

ArticleFrontiers in pharmacology2024

Harnessing adrenergic blockade in stress-promoted TNBC

Yasmeen Attia, Andrew Hakeem, Rawda Samir, Aya Mohammed, Abdullrahman Elsayed, Alaa Khallaf, Eman Essam, Hossameldeen Amin, Sarah Abdullah, Salwan Hikmat and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yasmeen AttiaPharmacology Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Andrew HakeemPharmacology Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Rawda SamirHealth Research Center of Excellence, Drug Research and Development Group, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Aya MohammedPharmacology Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Abdullrahman ElsayedFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Alaa KhallafFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Eman EssamFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Hossameldeen AminFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Sarah AbdullahFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Salwan HikmatFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Tarek HossamFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Ziad MohamedFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Ziad AboelmagdFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Egypt.
Olfat HammamPathology Department, Theodor Bilharz Research Institute, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sympathetic activation triggered by chronic stress afflicting cancer survivors is an emerging modulator of tumorigenesis. Adrenergic blockade was previously associated with improving response to doxorubicin (DOX) in triple-negative breast cancer (TNBC), yet the precise underlying mechanisms remain obscure. The resilience of cancer stem cells (CSCs) during chemotherapy fosters resistance and relapse. Hypoxia-inducible factor-1α (HIF-1α) and β-catenin are intertwined transcriptional factors that enrich CSCs and evidence suggests that their expression could be modulated by systemic adrenergic signals. Herein, we aimed to explore the impact of adrenoreceptor blockade using carvedilol (CAR) on DOX and its potential to modulate CSCs overcoming chemoresistance. To achieve this aim,

Indexed as

cancer stem cellscarvediloldoxorubicinGSK-3βHIF-1αstresstriple negative breast cancerβ-catenin

Identifiers

PMID38962320
PMCPMC11220203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.